^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + Recentin (cediranib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Published date:
10/18/2022
Excerpt:
Patients with progressive metastatic castration-resistant prostate cancer (mCRPC) were randomly assigned 1:1 to arm A: cediranib 30 mg once daily plus olaparib 200 mg twice daily or arm B: olaparib 300 mg twice daily alone….BRCA2-mutated subgroups treated with olaparib with or without cediranib were associated with a numerically longer median rPFS.
DOI:
10.1200/JCO.21.02947
Trial ID:
